Advertisement
Canada markets close in 2 hours 9 minutes

  • S&P/TSX

    21,884.96
    -126.76 (-0.58%)
     

  • S&P 500

    5,077.63
    +7.08 (+0.14%)
     

  • DOW

    38,515.20
    +11.51 (+0.03%)
     

  • CAD/USD

    0.7298
    -0.0023 (-0.31%)
     

  • CRUDE OIL

    82.69
    -0.67 (-0.80%)
     

  • Bitcoin CAD

    88,865.70
    -2,708.43 (-2.96%)
     

  • CMC Crypto 200

    1,404.89
    -19.21 (-1.35%)
     

  • GOLD FUTURES

    2,335.70
    -6.40 (-0.27%)
     

  • RUSSELL 2000

    1,992.47
    -10.18 (-0.51%)
     

  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     

  • NASDAQ

    15,744.85
    +48.21 (+0.31%)
     

  • VOLATILITY

    15.82
    +0.13 (+0.83%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Asensus Surgical to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Asensus Surgical, Inc.
·2 min read
Asensus Surgical, Inc.
Asensus Surgical, Inc.

RESEARCH TRIANGLE PARK, N.C., March 06, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference. The Company’s virtual presentation will take place on Monday, March 13 at 2:00 pm Eastern Time.

The conference webcast will be available online on the investor relations page of the Company’s website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website for approximately 90 days.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance® Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com.

ADVERTISEMENT

Follow Asensus

Email Alerts: https://ir.asensus.com/email-alerts

LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc

Twitter: https://twitter.com/AsensusSurgical

YouTube: https://www.youtube.com/c/transenterix

Vimeo: https://vimeo.com/asxc

TikTok: https://www.tiktok.com/@asensus_surgical

INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com

MEDIA CONTACT:
Isabella Rodriguez, 708-833-1572
CG Life
irodriguez@cglife.com